Adasuve is an orally inhaled medicine containing loxapine, a medium-dose, first-generation antipsychotic, for the treatment of mild to moderate agitation in adults with schizophrenia or bipolar disorder. The maximum plasma concentration is achieved within 2 minutes with a dose of 9.1 mg loxapine delivered through the Staccato inhaler, and an effect is seen within 10 minutes. However, comparable clinical trials with an active comparator have not been made, and therefore the effect of Adasuve compared to traditional treatment for acute agitation cannot be assessed.
Adasuve must only be administered in hospitals under the supervision of healthcare professionals, which is why Adasuve is not used for treatment in the primary care.
It is IRF's overall assessment that Adasuve may be an alternative in the treatment of acute agitation: The fast onset of action may reduce the need for intramuscular injection, which may be traumatic for the patient and increase the risk of injection accidents for healthcare providers. In addition, self-administration of Adasuve may reduce the risk of escalated agitation. However, Adasuve is more expensive than intramuscular formulations of second-generation antipsychotics, e.g. olanzapine, and intramuscular formulations of first-generation antipsychotics, e.g. haloperidol.
Adasuve was marketed on 14 April 2014.